1 |
Zaman, G. J. R., Versantvoort, C. H. M., Smit, J. J. M., Eijdems,
E. W. H. M., De Haas, M., Smith, A. J., Broxterman, H. J.,
Mulder, N. H., De Vries, E. G. E., Baas, F. and Borst, P.
(1993). Analysis of the expression of MRP, the gene for a
new putative transmembrane drug transporter, in human
multidrug resistant lung cancer cell lines. Cancer Res. 53,
1747-1750.
|
2 |
Toppmeyer, D., Seidman, A. D., Pollak, M., Russell, C., Tkaczuk,
K., Verma, S., Overmoyer, B., Garg, V., Ette, E., Harding, M.
W. and Demetri, G. D. (2002). Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in
combination with paclitaxel for advanced breast cancer
refractory to paclitaxel. Clin. Cancer Res. 8, 670-678.
|
3 |
Van Zanden, J. J., De Mul, A., Wortelboer, H. M., Usta, M., van
Bladeren, P. J., Ivonne, M. C., Rietjens, M., Nicole, H. and
Cnubben, P. (2005). Reversal of in vitro cellular MRP1 and
MRP2 mediated vincristine resistance by the flavonoid
myricetin. Biochem. Pharmacol. 69, 1657-1665.
DOI
|
4 |
Viale, M., Cordazzo, C., Cosimelli, B., de Totero, D.,
Castagnola, P., Aiello, C., Severi, E., Petrillo, G., Cianfriglia,
M. and Spinelli, D. (2009). Inhibition of MDR1 activity in vitro
by a novel class of diltiazem analogues: toward new
candidates. J. Med. Chem. 52, 259-266.
DOI
|
5 |
Wada, M. (2006). Single nucleotide polymorphisms in ABCC2
and ABCB1 genes and their clinical impact in physiology and
drug response. Cancer Letter 234, 40-50.
DOI
|
6 |
Weiss, J., Sauer, A., Frank, A. and Unger, M. (2005). Extracts
and kavalactones of Piper methysticum G. Forst (kava-kava)
inhibit P-glycoprotein in vitro. Drug Metab. Dispos. 33,
1580-1583.
DOI
|
7 |
Wu, C. P., Calcagno, A. M., Hladky, S. B., Ambudkar, S. V. and
Barrand, M. A. (2005). Modulatory effects of plant phenols
on human multidrug-resistance proteins 1, 4 and 5 (ABCC1,
4 and 5). FEBS J. 272, 4725-4740.
DOI
|
8 |
Xia, Y., Min, K. H. and Lee, K. (2009). Synthesis and Biological
Evaluation of Decursin, Prantschimgin and Their Derivatives.
Bull. Korean Chem. Soc. 30, 43-48.
DOI
|
9 |
Yu, S. T., Chen, T. M., Tseng, S. Y. and Chen, Y. H. (2007).
Tryotanthrin inhibits MDR1 and reverses doxorubicin resistance
in breast cancer cells. Biochem. Biophys. Res.
Commun. 358, 79-84.
DOI
|
10 |
Romiti, N., Pellati, F., Nieri, P., Benvenuti, S., Adinolfi, B. and
Chieli, E. (2008). P-glycoprotein inhibitory activity of lipophilic
constituents of Echinacea pallida roots in a human proximal
tubular cell lines. Planta Med. 74, 264-266.
DOI
|
11 |
Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P.,
Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S. G.,
Hammond, L., Kraynak, M., Drengler, R., Stephenson, J. J.,
Harding, M. W. and Von Hoff, D. D. (1998). Phase I and
pharmacokinetic study of paclitaxel in combination with
biricodar, a novel agent that reverses multidrug resistance
conferred by overexpression of both MDR1 and MRP. J.
Clin. Oncol. 16, 2964-2976.
DOI
|
12 |
Rubio, G. J., Pinedo, H. M., Gazdar, A. F., Van Ark-Otte, J. and
Giaccone, G. (1994). MRP gene assessment in human
cancer, normal lung, and lung cancer cell lines. Proc. Am.
Assoc. Cancer Res. 35, 206.
|
13 |
Theis, J. G., Chan, H. S., Greenberg, M. L., Malkin, D., Karaskov,
V., Moncica, I., Koren, G. and Doyle, J. (2000). Assessment
of systemic toxicity in children receiving chemotherapy with
cyclosporine for sarcoma. Med. Pediatr. Oncol. 34, 242-249.
DOI
|
14 |
Shukla, S., Wu, C. P., and Ambudkar, S. V. (2008). Development
of inhibitors of ATP-binding cassette drug transporters -
present status and challenges. Expert Opin. Drug Metab.
Toxicol. 4, 205-223.
DOI
|
15 |
Skupien, K., Kostrzewa-Nowak, D., Oszmianski, J. and Tarasiuk,
J. (2008). In vitro antileukemia activity of extracts from
chokeberry (Aronia melanocarpa [Michx] Elliot) and mulberry
(Morus alba L.) leaves against sensitive and multidrug
resistant HL60 cells. Phytother. Res. 22, 689-694.
DOI
|
16 |
Takahashi, K., Kimura, Y., Nagata, K., Yamamoto, A., Matsuo,
M. and Ueda, K. (2005). ABC proteins: key molecules for
lipid homeostasis. Med. Mol. Morphol. 38, 2-12.
DOI
|
17 |
Thomas, H. and Coley, H. M. (2005). Overcoming multidrug
resistance in cancer: an update on the clinical strategy of
inhibiting p-glycoprotein. Cancer Control 10, 159-165.
|
18 |
Martelli, C., Coronnello, M., Dei, S., Manetti, D., Orlandi, F.,
Scapecchi, S., Romanelli, M. N., Salerno, M., Mini, E. and
Teodori, E. (2010). Structure-activity relationships studies in
a series of N,N-Bis(alkanol)amine aryl esters as P-Glycoprotein
(Pgp) dependent multidrug resistance (MDR)
inhibitors. J. Med. Chem. 53, 1755-1762.
DOI
|
19 |
Min, K. H., Xia, Y., Kim, E. K., Jin, Y. L., Kaur, N., Kim, E. S.,
Kim, D. K., Jung, H. Y., Choi, Y., Park, M. K., Min, Y. K., Lee,
K. and Lee, K. (2009). A novel class of highly potent
multidrug resistance reversal agents: Disubstituted adamantyl
derivatives. Bioorg. Med. Chem. Lett. 19, 5376-5379.
DOI
|
20 |
Nakamura, M., Abe, Y., Katoh, Y., Oshika, Y., Hatanaka, H.,
Tsuchida, T., Yamazaki, H., Kijima, H., Inoue, H. and
Ueyama, Y. (2000). A case of pulmonary adencarcinoma
with overexpression of multidrug resistance associated
protein and p53 aberration. Anticancer Res. 20, 1921-1925.
|
21 |
Newman, M. J., Rodarte, J. C., Benbatoul, K. D., Romano, S. J.,
Zhang, C., Krane, S., Moran, E. J., Uyeda, R. T., Dixon, R.,
Guns, E. S. and Mayer, L. D. (2000). Discovery and characterization
of OC144-093, a novel inhibitor of P-glycoproteinmediated
multidrug resistance. Cancer Res. 60, 2964-2972.
|
22 |
Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi,
T., Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B.,
Berk, D. A. and Jain, R. K. (2001). Role of tumor-host interactions
in interstitial diffusion of macromolecules: cranial vs.
subcutaneous tumors. Proc. Natl. Acad. Sci. 98, 4628-4633.
DOI
|
23 |
Polgar, O. and Bates, S. E. (2004). ABC transporters in the
balance: is there a role in multidrug resistance? Biochem.
Soc. Trans. 33, 241-245.
DOI
|
24 |
Raad, I., Terreux, R., Richomme, P., Matera, E. L., Dumontet,
C., Raynaud, J. and Guilet, D. (2006). Structure- activity
relationship of natural and synthetic coumarins inhibiting the
multidrug transporter P-glycoprotein. Bioorg. Med. Chem.
14, 6979-6987.
DOI
|
25 |
Kuhnle, M., Egger, M., Muller, C., Mahringer, A., Bernhardt,
G., Fricker,G., Konig, B. and Buschauer, A. (2009). Potent
and selective inhibitors of breast cancer resistance protein
(ABCG2) derived from the P-Glycoprotein (ABCB1)
modulator tariquidar. J. Med. Chem. 52, 1190-1197.
DOI
|
26 |
Leonard, G. D., Fojo, T. and Bates, S. E. (2003). The role of
ABC transporters in clinical practice. Oncologist 8, 411-424.
DOI
|
27 |
Li, Y., Zhang, H. B. and Huang, W. L. (2008). Design and
synthesis of tetrahydroisoquinoline derivatives as potential
multidrug resistance reversal agents in cancer. Bioorg. Med.
Chem. Lett. 18, 3652-3655.
DOI
|
28 |
Limtrakul, P., Siwanon, S., Yodkeeree, S. and Duangrat, C.
(2007b). Effect of Stemona curtisii root extract on
P-glycoprotein and MRP-1 function in multidrug-resistant
cancer cells. Phytomedicine 14, 381-389.
DOI
|
29 |
Limtrakul, P. (2007). Curcumin as chemosensitizer. Adv. Exp.
Med. Biol. 595, 269-300.
DOI
|
30 |
Limtrakul, P., Chearwae, W., Shukla, S., Phisalphong, C. and
Ambudkar, S. V. (2007a). Modulation of function of three
ABC transporters, P-glycoprotein (ABCB1), mitoxanthrone
resistance protein (ABCG2) and multidrug resistance protein
1 (ABCC1) by tetrahydrocurcumin, a major metabolite of
curcumin. Mol. Cell Biochem. 296, 85-95.
DOI
|
31 |
Liscovitch, M. and Lavie, Y. (2002). Cancer multidrug resistance:
a review of recent drug discovery research. Drugs 5,
349-355.
|
32 |
Liu, D. F., Li, Y. P., Ou, T. M., Huang, S. L., Gu, L. Q., Huang, M.
and Huang, Z. S. (2009). Synthesis and antimultidrug
resistance evaluation of icariin and its derivatives. Bioorg.
Med. Chem. Lett. 19, 4237-4240.
DOI
|
33 |
Longley, D. B. and Johnston, P. G. (2005). Molecular mechanisms
of drug resistance. J. Pathol. 205, 275-292.
DOI
|
34 |
Henrich, C. J., Bokesch, H. R., Dean, M., Bates, S. E., Robey,
R. W., Goncharova, E. I., Wilson, J. A. and McMahon, J. B.
(2006). A high-throughput cell-based assay for inhibitors of
ABCG2 activity. J. Biomol. Screen 11, 176-183.
DOI
|
35 |
Jin, J., Wang, F. P., Wei, H. and Liu, G. (2005). Reversal of
multidrug resistance of cancer through inhibition of Pglycoprotein
by 5-bromotetrandrine. Cancer Chemother.
Pharmacol. 55, 179-188.
DOI
|
36 |
Kim, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F.,
Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K.,
Roden, D. M., Wood, A. J. and Wilkinson, G. R. (1999).
Interrelationship between substrates and inhibitors of human
CYP3A and P-glycoprotein. Pharm. Res. 16, 408-414.
DOI
|
37 |
Katayama, K., Masuyama, K., Yoshioka, S., Hasegawa, H.,
Mitsuhashi, J. and Sugimoto, Y. (2007). Flavonoids inhibit
breast cancer resistance protein-mediated drug resistance:
transporter specificity and structure-activity relationship.
Cancer Chemother. Pharmacol. 60, 789-797.
DOI
|
38 |
Kellen, J. A. (2003). The reversal of multidrug resistance: an
update. J. Exp. Ther. Oncol. 3, 5-13.
DOI
|
39 |
Kim, D. H., Park, J. Y., Sohn, S. K., Lee, N. Y., Baek, J. H., Jeon, S. B., Kim, J. G., Suh, J. S., Do, Y. R. and Lee, K. B.
(2006). Multidrug resistance-1 gene polymorphisms
associated with treatment outcomes in de novo acute
myeloid leukemia. Int. J. Cancer 118, 2195-2201.
DOI
|
40 |
Krishna, R. and Mayer, L. D. (2000). Multidrug resistance
(MDR) in cancer. Mechanisms, reversal using modulators of
MDR and the role of MDR modulators in influencing the
pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci.
11, 265-283.
DOI
|
41 |
Krug, M., Voigt, B., Baumert, C., Lupken, R., Molnar, J. and
Hilgeroth, A. (2010). First biological evaluation of developed
3-benzyloxyfluorenes as novel class of MDR modulators.
Eur. J. Med. Chem. 45, 2683-2688
DOI
|
42 |
Gottesman, M. M. (2002). Mechanisms of cancer drug resistance.
Annu. Rev. Med. 53, 615-627.
DOI
|
43 |
Gottesman, M. M., Fojo, T. and Bates, S. E. (2002). Multidrug
resistance in cancer: role of ATP-dependent transporters.
Nature Reviews Cancer 2, 48-58.
DOI
|
44 |
Hacker, H. G., Leyers, S., Wiendlocha, J., Gutschow, M. and
Wiese, M. (2009b). Aromatic 2-(Thio)ureidocarboxylic acids
as a new family of modulators of multidrug resistanceassociated
protein 1: synthesis, biological evaluation, and
structure-activity relationships. J. Med. Chem. 52, 4586-
4595.
DOI
|
45 |
Gottesman, M. M. and Pastan, I. (1996). Drug resistance:
alterations in drug uptake or extrusion. In Encyclopedia of
Cancer (J. R. Bertino, Ed.) pp. 549-559. Academic, San
Diego, CA.
|
46 |
Gruber, A., Bjorkholm, M., Brinch, L., Evensen, S., Gustavsson,
B., Hedenus, M., Juliusson, G., Löfvenberg, E., Nesthus, I.,
Simonsson, B., Sjo, M., Stenke, L., Tangen, J. M., Tidefelt,
U., Udén, A. M., Paul, C. and Liliemark, J. (2003). A phase
I/II study of the MDR modulator Valspodar (PSC 833)
combined with daunorubicin and cytarabine in patients with
relapsed and primary refractory acute myeloid leukemia.
Leuk. Res. 27, 323-328.
DOI
|
47 |
Hacker, H. G., de la Haye, A., Sterz, K., Schnakenburg, G.,
Wiese, M. and Gutschow, M. (2009a). Analogs of a
4-aminothieno[2,3-d]pyrimidine lead (QB13) as modulators
of P-glycoprotein substrate specificity. Bioorg. Med. Chem.
Lett. 19, 6102-6105.
DOI
|
48 |
Hao, X. Y., Widersten, M., Ridderstrom, M., Hellman, U. and
Mannervik, B. (1994). Covariation of glutathione transferase
expression and cytostatic drug resistance in HeLa cells:
establishment of class Mu glutathione transferase M3-3 as
the dominating isoenzyme. Biochem. J. 297, 59-67.
DOI
|
49 |
Jin, J., Shahi, S., Kang, H. K., Van Veen, H. W. and Fan, T. P.
(2006). Metabolism of ginsenosides as novel BCRP inhibitors.
Biochem. Biophys. Res. Commun. 345, 1308-1314.
DOI
|
50 |
Dantzig, A. H., Shepard, R. L., Law, K. L., Tabas, L., Pratt, S.,
Gillespie, J. S., Binkley, S. N., Kuhfeld, M. T., Starling, J. J.
and Wrighton, S. A. (1999). Selectivity of the multidrug resistance
modulator, LY335979, for P-glycoprotein and effect on
cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 290,
854-862.
|
51 |
Efferth, T. (2001). The human ATP-binding cassette transporter
genes: from the bench to the bedside. Curr. Mol. Med. 1,
45-65.
DOI
|
52 |
Das, U., Molnár, J., Bará th, Z., Bata, Z. and Dimmock, J. R. (2008).
1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis (benzylidene)-
4-oxopiperidines: a novel series of highly potent revertants of
P-glycoprotein associated multidrug resistance. Bioorg.
Med. Chem. Lett. 18, 3484-3487.
DOI
|
53 |
Dean, M., Rzhetsky, A. and Allikmets, R. (2001). The human
ATP-binding cassette (ABC) transporter superfamily. Genome
Res. 11, 1156-1166.
DOI
|
54 |
Demant, E. J., Sehested, M. and Jensen, P. B. (1990). A model
for computer simulation of P-glycoprotein and transmembrane
delta pH-mediated anthracycline transport in multidrug resistant
tumor cells. Biochim. Biophys. Acta. 1055, 117-125.
DOI
|
55 |
Fan, D., Beltran, P. J. and O’Brien, C. A. (1994). Reversal of
multidrug resistance. In Reversal of Multidrug Resistance in
Cancer (J. A. Kellen, Ed.), pp. 93-124. CRC Press, Boca
Raton, FL.
|
56 |
Fong, W. F., Shen, X. L., Globisch, C., Wiese, M., Chen, G. Y.,
Zhu, G. Y., Yu, Z. L., Tse, A. K. W. and Hue, Y. J. (2008).
Methoxylation of 3’,4’-aromatic side chains improves
P-glycoprotein inhibitory and multidrug resistance reversal
activities of 7,8-pyranocoumarin against cancer cells. Bioorg.
Med. Chem. 16, 3694-3703.
DOI
|
57 |
Ford, J. M. and Hait, W. N. (1990). Pharmacology of drugs that
alter multidrug resistance in cancer. Pharmacol. Rev. 42,
155-199.
|
58 |
Garcia, M., Jemal, A., Ward, E. M., Center, M. M., Hao, Y.,
Siegel, R. L. and Thun, M. J. (2007). Global Cancer Facts
and Figures 2007. American Cancer Society, Atlanta, GA.
|
59 |
Chearwae, W., Wu, C. P., Chu, H. Y., Lee, T. R., Ambudkar, S.
V. and Limtrakul, P. (2006). Curcuminoids purified from
tumeric powder modulate the function of human multidrug
resistance protein 1 (ABCC1). Cancer Chemother. Pharmacol.
57, 376-388.
DOI
|
60 |
Broxterman, H. J., Kuiper, C. M., Schuurhuis, G. J., Ossen koppele, G. J., Feller, N., Scheper, R. J., Lankelma, J. and
Pinedo, H. M. (1994). Analysis of P-glycoprotein (P-gp) and
non-P-gp multidrug resistance in acute myeloid leukemia.
Proc. Am. Assoc. Cancer Res. 35, 348.
|
61 |
Choi, C. H. (2005). ABC transporters as multidrug resistance
mechanisms and the development of chemosensitizers for
their reversal. Cancer Cell Int. 5, 30.
DOI
|
62 |
Coburger, C., Wollmann, J., Baumert, C., Krug, M., Molna´r, J.,
Lage, H. and Hilgeroth, A. (2008). Novel insight in structureactivity
relationship and bioanalysis of P-Glycoprotein targeting
highly potent tetrakishydroxymethyl substituted 3,9-
Diazatetraasteranes. J. Med. Chem. 51, 5871-5874.
DOI
|
63 |
Colabufo, N. A., Berardi, F., Cantore, M., Perrone, M. G., Contino,
M., Inglese, C., Niso, M., Perrone, R., Azzariti, A.,
Simone, G. M., Porcelli, L. and Paradiso, A. (2008a). Small
P-gp modulating molecules: SAR studies on tetrahydroisoquinoline
derivatives. Bioorg. Med. Chem. 16, 362-373.
|
64 |
Colabufo, N. A., Berardi, F., Perrone, R., Rapposelli, S., Digiacomo,
M., Vanni, M. and Balsamo, A. (2008b). Synthesis
and biological evaluation of (Hetero) arylmethyloxy- and arylmethylamine-
phenyl derivatives as potent P-glycoprotein
modulating agents. J. Med. Chem. 51, 1415-1422.
DOI
|
65 |
Colabufo, N. A., Berardi, F., Perrone, R., Rapposelli, S., Digiacomo,
M., Vanni, M. and Balsamo, A. (2008c). 2-[(3-Methoxyphenylethyl)
phenoxy]-based ABCB1 Inhibitors: effect of
different basic side-chains on their biological properties. J.
Med. Chem. 51, 7602-7613.
DOI
|
66 |
Anderle, P., Huang, Y. and Sadee, W. (2004). Intestinal membrane
transport of drugs and nutrients: Genomics of membrane
transporters using expression microarrays. Eur. J.
Pharm. Sci. 21, 17-24.
DOI
|
67 |
Abolhoda, A., Wilson, A. E., Ross, H., Denenberg, R. V., Burt,
M. and Scotto, K. W. (1999). Rapid activation of MDR1 gene
expression in human metastatic sarcoma after in vivo
exposure to doxorubicin. Clin. Cancer Res. 5, 3352-3356.
|
68 |
Almquist, K. C., Loe, D. W., Hipfner, D. R., Mackie, J. E., Cole,
S. P. and Deeley, R. G. (1995). Characterization of the M
190 000 multidrug resistance protein (MRP) in drug selected
and transfected human tumor cell. Cancer Res. 55, 102-110.
|
69 |
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M.,
Pastan, I. and Gottesman, M. M. (1999). Biochemical, cellular
and pharmacological aspects of the multidrug transporter.
Annu. Rev. Pharmacol. Toxicol. 34, 361-398.
|
70 |
Beck, J., Gekeler, V., Handgretinger, R. and Niethammer, D.
(1994). PCR gene expression analysis of multidrug resistance
associated genes in primary and relapsed state
leukemias: comparison of mdrl, mrp, topoisomerase IIa,
topoisomerase IIb and cyclin A mRNA levels. Proc. Am.
Assoc. Cancer Res. 35, 337.
|
71 |
Benet, L. Z. and Cummins, C. L. (2001). The drug efflux- metabolism
alliance: biochemical aspects. Adv. Drug Deliv. Rev.
50(Suppl 1), S3-S11.
DOI
|
72 |
Borst, P., Evers, R., Kool, M. and Wijnholds, J. (2000). A family
of drug transporters: the multidrug resistance-associated
proteins. J. Natl. Cancer Inst. 92, 1295-302.
DOI
|
73 |
Borst, P., Kool, M. and Evers, R. (1997). Do cMOAT (MRP2),
other MRP homologues, and LRP play a role in MDR.
Cancer Biol. 8, 205-213.
DOI
|